P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES

P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES

Bibliographic Details
Main Authors:	C. Harrison, J.-J. Kiladjian, A. M. Vannucchi, R. A. Mesa, R. M. Scherber, J. Hamer-Maansson, S. Verstovsek
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847016.73500.23

Similar Items

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
by: Alessandro M. Vannucchi, et al.
Published: (2015-09-01)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
by: Haifa Kathrin Al-Ali, et al.
Published: (2023-08-01)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
by: Nico Gagelmann, et al.
Published: (2023-08-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
by: C. Harrison, et al.
Published: (2022-06-01)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
by: Srdan Verstovsek, et al.
Published: (2021-09-01)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
by: V. Gupta, et al.
Published: (2022-06-01)

<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
by: Srdan Verstovsek, et al.
Published: (2024-04-01)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
by: J.-J. Kiladjian, et al.
Published: (2022-06-01)

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
by: Ruben A. Mesa, et al.
Published: (2014-02-01)

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
by: Vikas Gupta, et al.
Published: (2016-12-01)

Therapy-related myelofibrosis does not appear to exist
by: Lucia Masarova, et al.
Published: (2017-06-01)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
by: Claire N. Harrison, et al.
Published: (2021-05-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
by: Verstovsek, S, et al.
Published: (2021)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
by: A. Vannucchi, et al.
Published: (2022-06-01)

P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY
by: A. T. Gerds, et al.
Published: (2022-06-01)

P1045: DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST
by: Rami S. Komrokji, et al.
Published: (2023-08-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
by: Marina Kremyanskaya, et al.
Published: (2023-08-01)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
by: Harrison, C, et al.
Published: (2023)

S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR
by: S. Verstovsek, et al.
Published: (2022-06-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
by: Mesa, RA, et al.
Published: (2023)

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
by: Mesa, R, et al.
Published: (2017)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
by: A. Vannucchi, et al.
Published: (2022-06-01)

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
by: J. Mascarenhas, et al.
Published: (2022-06-01)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
by: Jean-Jacques Kiladjian, et al.
Published: (2023-11-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
by: Prithviraj Bose, et al.
Published: (2020-08-01)

'Praesul praecipue, atque venerande': the career of Robert, archbishop of Rouen, 989-1037
by: Allen, R
Published: (2013)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
by: Aaron T. Gerds, et al.
Published: (2023-08-01)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib
by: Ruben Mesa, et al.
Published: (2023-06-01)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
by: Helen T. Chifotides, et al.
Published: (2022-01-01)

Defining disease modification in myelofibrosis in the era of targeted therapy
by: Pemmaraju, N, et al.
Published: (2022)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
by: Ruben A. Mesa, et al.
Published: (2021-05-01)

S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY
by: J. Mascarenhas, et al.
Published: (2022-06-01)

Guideline for the diagnosis and management of myelofibrosis
by: Reilly, J, et al.
Published: (2012)

Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
by: V. Gupta, et al.
Published: (2022-06-01)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
by: C. Harrison, et al.
Published: (2022-06-01)

Recent developments in myelofibrosis
by: Mesa RA, et al.
Published: (2012-07-01)